Free Trial

Halozyme Therapeutics (HALO) SEC Filings & 10K Form

Halozyme Therapeutics logo
$55.23 -0.71 (-1.28%)
As of 11:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recent Halozyme Therapeutics SEC Filings

DateFilerForm TypeView
01/08/2025
7:00 AM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2025
3:14 PM
Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2025
4:12 PM
Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2025
3:26 PM
Halozyme Therapeutics (Subject)
Henderson Jeffrey William (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/12/2024
8:36 AM
Artisan Partners Limited Partnership (Filed by)
Halozyme Therapeutics (Subject)
Form SC 13G/A
10/31/2024
3:05 PM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2024
8:36 AM
Halozyme Therapeutics (Subject)
STATE STREET CORP (Filed by)
Form SC 13G
10/16/2024
5:53 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2024
3:14 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/15/2024
3:34 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/09/2024
4:39 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/09/2024
3:09 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/08/2024
3:08 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/26/2024
5:06 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2024
3:00 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/24/2024
3:05 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/18/2024
5:49 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2024
3:01 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
4:56 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2024
3:12 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/11/2024
3:05 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2024
3:16 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/27/2024
6:49 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2024
5:03 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
3:16 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2024
3:59 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/15/2024
3:31 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2024
3:19 PM
Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
3:41 PM
Halozyme Therapeutics (Subject)
Posard Matthew L. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/24/2024
4:48 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/24/2024
3:05 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/23/2024
3:11 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/22/2024
3:13 PM
Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/28/2024
3:51 PM
Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/27/2024
3:29 PM
Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2024
3:16 PM
Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/20/2024
3:17 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2024
3:22 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/14/2024
3:17 PM
Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2024
3:40 PM
Halozyme Therapeutics (Subject)
Posard Matthew L. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/22/2024
4:24 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Donald Trump is about to free crypto from its chains … (Ad)

With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.

This coin may be Trump’s favorite crypto …
05/07/2024
3:05 PM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2024
4:54 PM
Duncan Barbara Gayle (Reporting)
Halozyme Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
4:56 PM
Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
5:01 PM
Halozyme Therapeutics (Issuer)
Krishnan Mahesh (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
5:05 PM
Halozyme Therapeutics (Issuer)
MATSUI CONNIE (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
5:08 PM
Halozyme Therapeutics (Issuer)
Miyashita Akiko Moni (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
5:11 PM
Halozyme Therapeutics (Issuer)
Posard Matthew L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2024
4:51 PM
Connaughton Bernadette (Reporting)
Halozyme Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/26/2024
3:22 PM
Halozyme Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2024
6:22 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2024
6:38 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
3:46 PM
Halozyme Therapeutics (Filer)
Form ARS
03/15/2024
3:18 PM
Halozyme Therapeutics (Filer)
Form DEFA14A
03/13/2024
4:22 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2024
3:14 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
3:13 PM
Halozyme Therapeutics (Filer)
Form PRE 14A
02/28/2024
5:49 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/28/2024
3:07 PM
Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/20/2024
5:53 PM
Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
5:55 PM
Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
5:59 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2024
5:49 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:39 PM
Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:41 PM
Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
4:47 PM
Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2024
5:19 AM
Artisan Partners Limited Partnership (Filed by)
Halozyme Therapeutics (Subject)
Form SC 13G/A
02/01/2024
2:51 PM
Halozyme Therapeutics (Subject)
Invesco Ltd. (Filed by)
Form SC 13G/A
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:HALO) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners